NEWS & EVENTS
The management of Ergomed (AIM:ERGO.L), which offers clinical trials and pharmacovigilance services to pharmaceutical companies, while also co-developing a product …READ MORE
$HCM Hutch Chi Med. More Director buying of shares / ADSs this morning. Directors have bought on about 8 dates since H1 results in July
$CLIN @Clinigen again in demand. Through 1000p for the first time last week and now hitting 1100p. Awaiting news re Quantum Pharma tie up..
$PHD.L @proactisgroup shares up on trading update: 'substantial' progress, revs + 31% to £25.4m, adj PBT £5.3m, 110 up-sell and cross deals.
$TSTL @TristelGlobal new high 300p. Shares have been very strong performers over last 4 years on continuing +ve newsflow & upgrades
$BMK.L renews sales/marketing deal for 10 years with GSL re artemia harvest. Big scale (£30m revs in 2016) so excellent news for visibility.
WHY CHOOSE ED
"The team at ED consistently produce high quality research and highlight profitable investment opportunities, an invaluable tool for small cap investors in this under researched space."
"There is a need now, more than ever before, for real insight and clarity to be brought to company messages for investors….I would strongly recommend Equity Development to the management of any company."
Small Cap Equity Salesman
"I am delighted to go on record that Equity Development has done a very thorough and effective job for us in the last 9 months. In that period our share price has nearly doubled, and ED has published 7 notes to explain our results, acquisitions and key announcements. It has been very useful to stimulate interest amongst private investors, many of whom I have also enjoyed meeting. The timely and incisive notes have also gone down well with institutions. Last, and by no means least, ED’s willingness to work as part of a team alongside my Broker and PR firm has meant that this is a very simple relationship to manage."
"Thanks for working over the weekend on this – it is really appreciated, as always Benchmark gets massive benefit from ED’s work for us, and from your team’s wise counsel at these key moments."